Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure

Smokeless Tobacco Clinical Trial

Official title:
Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure

Status Recruiting

Clinical Trial Summary

Our goal in this study is to investigate the extent of endogenous nitrosation of nornicotine in smokeless tobacco users as a function of nornicotine content in smokeless products. This study will lead to an understanding of the endogenous formation of NNN from nornicotine in humans, and will also investigate the effect of the reduction of nornicotine content in smokeless tobacco on the extent of endogenous NNN formation. The knowledge gained in this study will lead to the development of recommendations for the regulation, or potentially elimination, of nornicotine in smokeless tobacco products in order to minimize exposure to NNN in the users of these products.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Smokeless Tobacco

Clinical Trial Details

NCT number	NCT03998735
Study type	Interventional
Source	Masonic Cancer Center, University of Minnesota
Contact	Hanna Vanderloo, RN, MSN
Phone	612-624-4983
Email	hannav@umn.edu
Status	Recruiting
Phase	Phase 1
Start date	October 19, 2021
Completion date	October 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00265681` - Telephone Counseling for Snuff Users	N/A
Completed	`NCT01249339` - In-vivo Extraction of Pb, Cd andTSNA From Swedish Snus	Phase 1
Completed	`NCT01369693` - In-vivo Extraction of Pb, Cd and TSNA From Swedish Snus	Phase 1
Withdrawn	`NCT01100216` - Human Laboratory Study of Smokeless Tobacco Products	N/A
Active, not recruiting	`NCT02994082` - Treating Smokeless Tobacco Use in Rural Veterans	N/A
Completed	`NCT00414180` - Bupropion SR for Treating Smokeless Tobacco Use	Phase 3